CIK 0001815776 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
LENZ Therapeutics, Inc.
Sign in to watch- Ticker
- LENZ
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 844867570
- Phone
- 858-925-7000
- Business address
- 201 LOMAS SANTA FE DRIVE, SUITE 300, SOLANA BEACH, CA, 92075
- Former names
- Graphite Bio, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $9,134,778
- in 1 filing
Net −$9,134,778. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-06-29 | Samsara BioCapital, L.P. 10% owner | Purchase | +15,000 | $17.00 | $255K | 37,753 |
| 2021-06-29 | Samsara BioCapital, L.P. 10% owner | Conversion · Series A Redeemable Convertible Preferred Stock | −15,000,000 | 0 | ||
| 2021-06-29 | Samsara BioCapital, L.P. 10% owner | Conversion · Series B Redeemable Convertible Preferred Stock | −1,802,372 | 0 | ||
| 2021-06-29 | Samsara BioCapital, L.P. 10% owner | Conversion · Series B Redeemable Convertible Preferred Stock | −55,336 | 0 | ||
| 2021-06-29 | Versant Venture Capital VI, L.P. 10% owner | Conversion | +12,343,727 | 14,708,398 | ||
| 2021-06-29 | Versant Venture Capital VI, L.P. 10% owner | Conversion | +1,527,719 | 1,527,719 | ||
| 2021-06-29 | Versant Venture Capital VI, L.P. 10% owner | Purchase | +180,000 | $17.00 | $3.1M | 1,707,719 |
| 2021-06-29 | Versant Venture Capital VI, L.P. 10% owner | Conversion · Series A Preferred Stock | −30,019,945 | 0 | ||
| 2021-06-29 | Versant Venture Capital VI, L.P. 10% owner | Conversion · Series B Preferred Stock | −3,715,415 | 0 | ||
| 2021-06-29 | Jerel Davis Director | Conversion | +12,343,727 | 14,708,398 | ||
| 2021-06-29 | Jerel Davis Director | Conversion | +1,527,719 | 1,527,719 | ||
| 2021-06-29 | Jerel Davis Director | Purchase | +180,000 | $17.00 | $3.1M | 1,707,719 |
| 2021-06-29 | Jerel Davis Director | Conversion · Series A Preferred Stock | −30,019,945 | 0 | ||
| 2021-06-29 | Jerel Davis Director | Conversion · Series B Preferred Stock | −3,715,415 | 0 | ||
| 2021-06-29 | Gutry Phil CHIEF BUSINESS OFFICER | Conversion | +8,126 | 293,471 | ||
| 2021-06-29 | Gutry Phil CHIEF BUSINESS OFFICER | Conversion · Series B Preferred Stock | −19,763 | 0 | ||
| 2021-06-29 | Stultz Katherine V CHIEF OPERATING OFFICER | Conversion | +8,126 | 216,020 | ||
| 2021-06-29 | Stultz Katherine V CHIEF OPERATING OFFICER | Conversion · Series B Preferred Stock | −19,763 | 0 | ||
| 2021-06-29 | Shah Smital Director | Purchase | +5,882 | $17.00 | $100K | 5,882 |
| 2021-06-29 | JIMENEZ JOSEPH Director | Conversion | +8,126 | 161,941 |
Page 9 of 11 · 217 trades